HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on BriaCell Therapeutics (NASDAQ:BCTX) and maintained a $25 price target.
June 28, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BriaCell Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $25.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in BriaCell Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100